Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Lin Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6798-023X; OpenAlex author ID A5100412894. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper

Papers 7

  1. The diagnostic significance of the ZNF gene family in pancreatic cancer: a bioinformatics and experimental study. Co-author DOI 10.3389/fgene.2023.1089023↗
  2. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. Co-author DOI 10.1038/s41419-022-04669-0↗
  3. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.02.035↗
  4. Identification of pyroptosis-related gene signature for predicting prognosis of patients with pancreatic cancer using bioinformatics. Co-author DOI 10.1097/md.0000000000031043↗
  5. The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Co-author DOI 10.1126/scitranslmed.abb5445↗
  6. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. Co-author DOI 10.1186/s13046-020-01687-8↗
  7. Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mi… Co-author DOI 10.1097/mpa.0000000000000183↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiyu Chen · 2 shared papers, 2020–2022 · strength 0.29
  2. Zhiwei He · 2 shared papers, 2020–2022 · strength 0.29
  3. Patrick M. Grierson · 2 shared papers, 2021–2022 · strength 0.26
  4. Daoxiang Zhang · 2 shared papers, 2021–2022 · strength 0.26
  5. Paarth B. Dodhiawala · 2 shared papers, 2021–2022 · strength 0.26
  6. Kian‐Huat Lim · 2 shared papers, 2021–2022 · strength 0.26
  7. Zhongbo Xu · 1 shared paper, 2022 · strength 0.22
  8. Guojuan Wang · 1 shared paper, 2022 · strength 0.22
  9. Lei Zhu · 1 shared paper, 2023 · strength 0.19
  10. Hong Zhu · 1 shared paper, 2023 · strength 0.19
  11. Dijie Zheng · 1 shared paper, 2022 · strength 0.15
  12. Kun Cai · 1 shared paper, 2022 · strength 0.15
  13. Yanqing Liu · 1 shared paper, 2022 · strength 0.15
  14. Cheng-Yi Sun · 1 shared paper, 2022 · strength 0.15
  15. Chao Yu · 1 shared paper, 2022 · strength 0.15
  16. Varintra E. Lander · 1 shared paper, 2022 · strength 0.14
  17. Liang‐I Kang · 1 shared paper, 2022 · strength 0.14
  18. Vikas Somani · 1 shared paper, 2022 · strength 0.14
  19. David G DeNardo · 1 shared paper, 2022 · strength 0.14
  20. Chengyi Sun · 1 shared paper, 2020 · strength 0.13
  21. Hao Zhang · 1 shared paper, 2020 · strength 0.13
  22. Po Sing Leung · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.